Wedbush Maintains Neutral on Ultragenyx Pharmaceutical, Lowers Price Target to $23

Benzinga Newsdesk www.benzinga.com Negative 65.2%

Neg 65.2% Neu 0% Pos 0%

Wedbush analyst Laura Chico maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Neutral and lowers the price target from $30 to $23.